NCT06137144 · AstraZeneca
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
(PRIMAVERA)
What this study is about
This study is designed to evaluate the safety, tolerability, PK and preliminary effectiveness following taken by mouth administration of AZD3470 as a treatment given alone, and in combination with other anticancer agents in participants with haematologic malignancies.
View original scientific description
This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Interventions
DRUG
AZD3470
AZD3470 is a novel, potent and selective, second-generation, Methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5.
DRUG
Pembrolizumab
Pembrolizumab (CAS nr: 1374853-91-4 )
Primary outcome measures
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Time frame: From Screening continuously until 28 days after the last dose of study medication.
AEs: Number of patients with adverse events by system organ class and preferred term. SAEs: Number of patients with serious adverse events by system organ class and preferred term.
Incidence of DLTs (Dose Escalation Cohorts only)
Time frame: From first dose of AZD3470 to end of Cycle 1 (each cycle is 21 days).
In the Dose Escalation cohorts in Part A, the number of participants with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Adequate organ and bone marrow function.
- In Part A (dose escalation), participants must be aged ≥ 18 years at the time of signing the informed consent. In Part B (dose optimization/expansion), participants must be at least 15 years of age.
- Histologically confirmed documented diagnosis of r/r cHL based on criteria established by the World Health Organization
- Must provide FFPE baseline tumour tissue to meet the minimum tissue requirement for central MTAP expression determination.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Module 1 (cHL):
- At least 1 radiographically measurable, and/or FDG-avid lymphoma lesion \> 1.5 cm.
- Participants must have documented r/r active disease, must have previously received at least 3 prior lines of therapy (including Brentuximab V
Where
- Duarte, California
- Miami, Florida
- Atlanta, Georgia
- Boston, Massachusetts
- New York, New York
- Philadelphia, Pennsylvania
- Houston, Texas
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jun 24, 2026 · Source of record for eligibility and locations